Cargando…
Adequate Antithrombin III Level Predicts Survival in Severe COVID-19 Pneumonia
Critically ill patients with COVID-19 are at an increased thrombotic risk, hence thromboprophylaxis with heparin is considered mandatory. Antithrombin III (ATIII) is the most potent endogenous anticoagulant and is required for the clinical efficacy of heparin. Profound hypercoagulable and inflammato...
Autores principales: | Joshi, Deepti, Manohar, Sarat, Goel, Garima, Saigal, Saurabh, Pakhare, Abhijit P, Goyal, Abhishek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570439/ https://www.ncbi.nlm.nih.gov/pubmed/34754684 http://dx.doi.org/10.7759/cureus.18538 |
Ejemplares similares
-
Quality of Life Amongst Multidrug-Resistant TB Patients: An Exploratory Study About Distributive Dimensions and Interactions
por: Sharma, Shweta, et al.
Publicado: (2022) -
Azithromycin and survival in Streptococcus pneumoniae pneumonia: a retrospective study
por: Shorr, Andrew F, et al.
Publicado: (2013) -
Adequate Knowledge and Low Vaccination Rates of Hepatitis B Virus Infection Among Students, Medical, and Paramedical Persons in a Tertiary Care Teaching Hospital
por: Kandi, Venkataramana, et al.
Publicado: (2020) -
Prevalence of Hospital-Acquired Pneumonia Among Patients With Severe to Critical COVID-19 Pneumonia Given Tocilizumab
por: Adre, Lorenzo Abednego B, et al.
Publicado: (2023) -
Low-dose trimethoprim-sulfamethoxazole for the treatment of Pneumocystis jirovecii pneumonia (LOW-TMP): protocol for a phase III randomised, placebo-controlled, dose-comparison trial
por: Sohani, Zahra N., et al.
Publicado: (2022)